Sterile and Aseptic Supplement Formats: The Drug Boundary, Annex 1 and the Positioning Trap

US DSHEA Section 201(ff) defines a dietary supplement as a product intended to supplement the diet that is intended for ingestion in tablet, capsule, powder, softgel, gelcap or liquid form, and is not represented for use as a conventional food or as a sole item of a meal or the diet. Parenteral (injectable), ophthalmic and inhalation routes are categorically outside the dietary supplement definition — products administered by these routes are drugs regardless of ingredient composition. FDA enforcement is consistent — Warning Letters to IV vitamin clinic operators marketing infusions as 'supplements,' to manufacturers of nasal-spray products with vitamin actives positioned outside the OTC monograph, to inhalation products including glutathione, NAD+ and vitamin preparations. EU food supplement Directive 2002/46/EC and Member State implementing legislation similarly restrict supplements to oral preparations — parenteral, ophthalmic and inhalation products fall under EU pharmaceutical regulation (Directive 2001/83/EC) requiring marketing authorisation. UK MHRA, Health Canada (Natural Health Product Regulations restrict to oral plus limited topical), Australia TGA (Listed Medicines do not include sterile parenteral routes — Registered Medicines required), Japan PMDA and Korea MFDS apply similar categorical exclusions. The regulatory positioning rule is firm — any parenteral, ophthalmic or inhalation product requires drug-pathway authorisation, not supplement.

Revised EU GMP Annex 1 Manufacture of Sterile Medicinal Products (effective August 2023) is the global benchmark for sterile manufacturing, adopted and mirrored across PIC/S members. Annex 1 introduces the Contamination Control Strategy (CCS) — the integrated holistic risk-based approach to contamination prevention spanning facility design, personnel, equipment, materials, process and monitoring — as the explicit organising framework for sterile manufacturing quality. Cleanroom grade classification (A/B/C/D) is tightened with quantitative particle and viable monitoring thresholds, Grade A unidirectional airflow requirements (0.36-0.54 m/s at the work height with smoke study validation) and barrier technology (isolators preferred for new design, restricted access barrier systems acceptable). Operator intervention is the dominant contamination risk vector — Annex 1 requires intervention minimisation, design-for-no-intervention, validated aseptic technique with intervention tracking and analysis. Media fills (process simulation) requirements are clarified — frequency, batch size scaling, intervention representation and acceptance criteria. Continuous viable and non-viable particle monitoring is required in Grade A with rapid microbial detection methods encouraged. CCS documentation, gap assessment and remediation are the dominant Annex 1 implementation efforts across the global sterile manufacturing base.

USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations governs the compounding of sterile preparations in US pharmacies, hospitals and outsourcing facilities. The 2023 revision tightens beyond-use dating, environmental monitoring, personnel qualification (gowning, glove fingertip sampling) and competency testing. Compounding categories — Category 1 (CSP prepared in ISO 5 primary engineering control with limited BUD), Category 2 (CSP prepared in segregated compounding area meeting full <797> requirements with extended BUD), Category 3 (extended BUD requires extensive sterility testing and stability data per the 2023 revision). Section 503A of the Federal Food, Drug and Cosmetic Act permits patient-specific compounding by state-licensed pharmacies meeting <797> requirements without FDA cGMP registration. Section 503B Outsourcing Facilities are FDA-registered, hold cGMP-equivalent compliance and may compound without patient-specific prescription for office-stock use by clinical practitioners. USP <800> Hazardous Drugs — Handling in Healthcare Settings governs occupational exposure controls for compounding hazardous drugs including certain hormone, oncology and immunosuppressive preparations. IV vitamin clinic operations typically rely on 503A or 503B compounded preparations sourced from licensed compounding pharmacies, with the clinic operator responsible for state medical board compliance, prescribing controls and adverse-event reporting — not for compounding cGMP unless operating an in-house sterile compounding facility.

The commercial reality of the sterile-format supplement-adjacent market is segmented across legal pathways. IV vitamin clinics operate via compounding pharmacy supply (503A patient-specific or 503B office-stock) under state medical board oversight with physician supervision and clinic-level adverse-event reporting; brand-owner positioning is service-led (clinic visit, physician consultation) rather than product-led (no consumer product sale). Ophthalmic vitamin products require OTC monograph compliance or full New Drug Application — no DSHEA supplement pathway. Nasal-spray products with vitamin or botanical actives require OTC monograph or NDA — restrictive positioning. Inhalation products including glutathione, NAD+ and vitamin preparations are drug-classified — FDA enforcement against supplement positioning is consistent. The recurrent failure mode is brand-owner expansion from oral supplement portfolio into IV-clinic supply, nasal spray or inhalation format with retained supplement marketing — triggering FDA Warning Letter, EU national enforcement, payment-processor termination and reputation damage. Positioning discipline requires clear classification per SKU, supplement positioning restricted to compliant oral format and sterile/parenteral/ophthalmic/inhalation products routed through the appropriate drug or compounding pathway.